CD166 is a marker of prostate cancer progression with a role in metastasis to bone, and is known to be shed from prostatic cancer cells by the action of the sheddase ADAM17, which was also detected with abundant biotinylated peptides [28]. Here, ADAM17 is linked to prostate carcinoma.